检索结果 - Li, Chi‐Chung
- Showing 1 - 12 results of 12
-
1
-
2
Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling 由 Hosseini, Iraj, Gadkar, Kapil, Stefanich, Eric, Li, Chi-Chung, Sun, Liping L., Chu, Yu-Waye, Ramanujan, Saroja
出版 2020Text -
3
-
4
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients 由 Netterberg, Ida, Li, Chi‐Chung, Molinero, Luciana, Budha, Nageshwar, Sukumaran, Siddharth, Stroh, Mark, Jonsson, E. Niclas, Friberg, Lena E.
出版 2018Text -
5
-
6
-
7
Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment 由 Li, Chi‐Chung, Voss, Tiffini, Kowalski, Ken, Yang, Bei, Kleijn, Huub Jan, Jones, Christopher J., Bosch, Rolien, Michelson, David, DeAngelis, Matthew, Xu, Yang, Xie, Iris, Kothare, Prajakti A.
出版 2020Text -
8
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males 由 Ankrom, Wendy, Bondiskey, Phung, Li, Chi‐Chung, Palcza, John, Liu, Wen, Dockendorf, Marissa F., Matthews, Catherine, Panebianco, Deborah, Reynders, Tom, Wagner, John A., Jakate, Abhijeet, Mesens, Sofie, Kraft, Walter K., Marcantonio, Eugene E.
出版 2020Text -
9
Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist 由 Li, Chi-Chung, Vermeersch, Steve, Denney, William S, Kennedy, William P, Palcza, John, Gipson, Adrianna, Han, Tae H, Blanchard, Rebecca, De Lepeleire, Inge, Depré, Marleen, Murphy, M Gail, Van Dyck, Kristien, de Hoon, Jan N
出版 2015Text -
10
Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program 由 Galluppi, Gerald R., Brar, Satjit, Caro, Luzelena, Chen, Yuan, Frey, Nicolas, Grimm, Hans Peter, Rudd, Deanne Jackson, Li, Chi‐Chung, Magee, Mindy, Mukherjee, Arnab, Nagao, Lee, Purohit, Vivek S., Roy, Amit, Salem, Ahmed Hamed, Sinha, Vikram, Suleiman, Ahmed A., Taskar, Kunal S., Upreti, Vijay V., Weber, Benjamin, Cook, Jack
出版 2021Text -
11
Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974) 由 Sinclair, Simon R, Kane, Stefanie A, Van der Schueren, Bart J, Xiao, Alan, Willson, Kenneth J, Boyle, Janet, de Lepeleire, Inge, Xu, Yang, Hickey, Lisa, Denney, William S, Li, Chi-Chung, Palcza, John, Vanmolkot, Floris H M, Depré, Marleen, Van Hecken, Anne, Murphy, M Gail, Ho, Tony W, de Hoon, Jay N
出版 2010Text -
12
Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist 由 Bell, Ian M., Gallicchio, Steven N., Wood, Michael R., Quigley, Amy G., Stump, Craig A., Zartman, C. Blair, Fay, John F., Li, Chi-Chung, Lynch, Joseph J., Moore, Eric L., Mosser, Scott D., Prueksaritanont, Thomayant, Regan, Christopher P., Roller, Shane, Salvatore, Christopher A., Kane, Stefanie A., Vacca, Joseph P., Selnick, Harold G.
出版 2010Text